NOVARTIND.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 spal. 2023 @ 13:00):

Stats
Šios dienos apimtis	11 685.00
Vidutinė apimtis	5 696.00
Rinkos kapitalizacija	16.64B
EPS	INR10.76 ( 2024-02-13 )
Kita pelno data	( INR0 ) 2024-05-10
Last Dividend	INR37.50 ( 2023-07-20 )
Next Dividend	INR0 ( N/A )
P/E	21.75
ATR14	INR12.22 (1.82%)

Tūris Koreliacija

Ilgas: 0.74 (moderate)

Trumpas: 0.00 (neutral)

Signal:(25.341) Neutral

Novartis India Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Novartis India Limited Koreliacija - Valiuta/Žaliavos

0.80
( moderate )

0.82
( strong )

-0.13
( neutral )

0.86
( strong )

0.35
( neutral )

-0.69
( moderate negative )

Novartis India Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR3.79B
Bruto pelnas:	INR1.77B (46.75 %)
EPS:	INR41.86

FY	2022
Pajamos:	INR3.79B
Bruto pelnas:	INR1.77B (46.75 %)
EPS:	INR41.86

FY	2022
Pajamos:	INR3.88B
Bruto pelnas:	INR2.06B (53.18 %)
EPS:	INR-1.510

FY	2021
Pajamos:	INR3.66B
Bruto pelnas:	INR2.16B (59.07 %)
EPS:	INR8.46

Financial Reports:

No articles found.

Novartis India Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR10.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR37.50 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Novartis India Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.04 - low (34.25%) | Divividend Growth Potential Score: 3.98 - Decrease likely (20.47%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR10.00	2021-08-17
Last Dividend	INR37.50	2023-07-20
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	INR57.50	--
Avg. Dividend % Per Year	2.07%	--
Score	2.56	--
Div. Sustainability Score	4.04
Div.Growth Potential Score	3.98
Div. Directional Score	4.01	--

Next Divdend (Est)
(2024-07-01)

INR65.00 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

2.56

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2021	INR10.00	1.45%
2022	INR10.00	1.28%
2023	INR37.50	5.57%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TINPLATE.NS	Dividend Junior	2023-08-11	Annually	19	0.72%
PDMJEPAPER.NS	Dividend Junior	2023-08-03	Annually	9	0.65%
J&KBANK.NS	Dividend Junior	2023-08-17	Sporadic	22	0.47%
DATAMATICS.NS	Dividend Junior	2023-09-22	Annually	21	0.49%
SHYAMMETL.NS	Dividend Junior	2023-06-05	Semi-Annually	4	0.70%
MAXHEALTH.NS	Dividend Junior	2023-09-08	Insufficient data to determine frequency	2	0.07%
GSPL.NS	Dividend Junior	2023-09-01	Annually	19	0.81%
BANKINDIA.NS	Dividend Junior	2023-06-20	Sporadic	23	1.34%
PRAJIND.NS	Dividend Junior	2023-07-19	Annually	22	0.83%
KABRAEXTRU.NS	Dividend Junior	2023-07-13	Annually	23	0.83%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.289	1.500	4.21	6.32	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.129	1.500	9.67	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	70.26	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	2.16	2.00	9.28	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.16	2.00	8.92	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.427	1.000	6.21	6.21	[0.2 - 0.8]
operatingProfitMarginTTM	0.347	1.000	5.06	5.06	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.04

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.42	1.000	8.34	0	[1 - 100]
returnOnEquityTTM	0.129	2.50	9.79	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.16	2.00	9.28	10.00	[0 - 30]
dividendYielPercentageTTM	5.56	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.16	2.00	9.28	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.148	1.500	-4.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0162	1.000	-2.10	0	[0.1 - 0.5]
Total Score				3.98

Novartis India Limited

Novartis India Limited operates as a healthcare company in India. It offers pharmaceutical products in the areas of bone and pain, calcium portfolio, gynecology, and neurosciences, as well as generics products in the areas of gynecology, anti-TB, and anti-infectives. The company provides central nervous system products under the Tegrital and Exelon brands; pain and inflammation products under the Voveran brand; and transplantation/immunology products under the Simulect, Certican, Myfortic, and Sandimmun Neoral brands. The company was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.